Outside the Guidelines: Denosumab Overuse in Prostate Cancer
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.
Medscape Medical News
source https://www.medscape.com/viewarticle/outside-guidelines-denosumab-overuse-prostate-cancer-2024a100044b?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/outside-guidelines-denosumab-overuse-prostate-cancer-2024a100044b?src=rss
Comments
Post a Comment